Sanofi bets on safer aspirin combos with $35M Pozen deal

Sanofi ($SNY) is handing over a $15 million upfront payment along with promises of $20 million in precommercialization milestones to partner with Chapel Hill, NC-based Pozen ($POZN) on a pair of new-and-improved aspirins that avoid some common side effects. Report